Effects of relaxin on development of mesangial proliferative nephritis

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 300-303

  Ikegaya, Naoki ^a,b   Yoshida, Takuya ^b   Kohsaka, Tetsuya ^a   Suzuki, Ayumi ^b   Kobayashi, Natsuki ^b   Yamamoto, Tatsuo ^c   Fujigaki, Yoshihide ^c   Hishida, Akira ^c   Kumagai, Hiromichi ^b  

^a SHIZUOKA UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

SMAD; TGF ; smooth muscle actin

Indexed keywords

HORMONE RECEPTOR; LGR7 RECEPTOR; RELAXIN; SMAD2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MESANGIUM CELL; NEPHRITIS; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; RAT;

RATTUS;

EID: 64549159371     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.03831.x     Document Type: Conference Paper

References (16)

1. Border, W.A. & N.A. Noble. 1994. Transforming growth factor beta in tissue fibrosis. N Engl. J. Med. 331: 1286-1292.
2. Youhua, L. 2006. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int. 69: 213-217.
3. Sherwood, O.D. 2004. Relaxin's physiological roles and other diverse actions. Endocr. Rev. 25: 205-234.
4. Gaedeke, J. & H. Peters. 2005. Relaxin: Exploring the antifibrotic potential of a pregnancy hormone. Kidney Int. 68: 405-406.
5. Samuel, C.S. & T.D. Hewitson. 2006. Relaxin in cardiovascular and renal disease. Kidney Int. 69: 1498-1502.
6. Garber, S.L., Y. Mirochnik, C.S. Brecklin, et al. 2001. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 59: 876-882.
7. Heeg, M.H., M.J. Koziolek, R. Vasko, et al. 2005. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 68: 96-109.
8. Yamamoto, T. & C.B. Wilson. 1987. Complement dependence of antibody-induced mesangial cell injury in the rat. J. Immunol. 138: 3758-3765.
9. Suzuki, H., T. Yamamoto, N. Ikegaya, et al. 2004. Dietary salt intake modulates progression of antithymo-cyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am. J. Physiol. Renal Physiol. 286: F267-F277.
10. Kohsaka, T., H. Takahara, K. Sugawara, et al. 1993. Endogenous heterogeneity of relaxin and sequence of the major form in pregnant sow ovaries. Biol. Chem. Hoppe Seyler 374: 203-210.
11. Kumagai, H., S. Katoh, K. Hirosawa, et al. 2002. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int. 62: 1219-1228.
12. Border, W.A., S. Okuda, L.R. Languino, et al. 1990. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346: 371-374.
13. Border, W.A., N.A. Noble, T. Yamamoto, et al. 1992. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360: 361-364.
14. Zoja, C.B., M. Abbate, D. Corna, et al. 1998. Phar-macologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am. J. Kidney Dis. 31: 453-463.
15. Johnson, R.J., H. Iida, C.E. Alpers, et al. 1991. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. α-Smooth muscle actin is a marker of mesangial cell proliferation. J. Clin. Invest. 87: 847-858.
16. Ando, Y., T. Moriyama, M. Miyazaki, et al. 1998. Enhanced glomerular expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Nephrol. Dial. Transplant. 13: 1168-1175.